GLP-1s linked to reduced risk for peptic ulcer disease

Key takeaways:

GLP-1 use was linked to lower risk for peptic ulcer disease among patients with type 2 diabetes.

These results suggest a possible gastrointestinal benefit with GLP-1 use for high-risk patients.

Use of GLP-1 receptor agonists was associated with 44% decreased odds of peptic ulcer disease among patients with type 2 diabetes, according to a retrospective study published in Clinical Gastroenterology and Hepatology.

Moreover, switching to GLP-1s as second-line therapy correlated with a 56% reduced risk for peptic ulcer disease compared with insulin.

“We’ll need more research to validate our findings and extend them to a population beyond type 2 diabetes, but this might make people more strongly consider using GLP-1 medications for people at higher risk for damage to t